Compounds > 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone
Page last updated: 2024-09-03

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and terutroban

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone has been researched along with terutroban in 1 studies

Compound Research Comparison

Studies
(3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone)		Trials
(3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone)		Recent Studies (post-2010)
(3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone)		Studies
(terutroban)		Trials
(terutroban)		Recent Studies (post-2010) (terutroban)
2502611324

Protein Interaction Comparison

ProteinTaxonomy3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone (IC50)terutroban (IC50)
Thromboxane A2 receptor Homo sapiens (human)0.0164

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Egan, KM; FitzGerald, GA; Fries, S; Lawson, JA; Lucitt, MB; Puré, E; Wang, M; Zukas, AM1

Other Studies

1 other study(ies) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and terutroban

ArticleYear
Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
    Circulation, 2005, Jan-25, Volume: 111, Issue:3

    Topics: Animals; Aorta; Arteriosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dietary Fats; Drug Interactions; Furans; Membrane Proteins; Mice; Naphthalenes; Propionates; Prostaglandin-Endoperoxide Synthases; Receptors, Thromboxane; Thromboxane A2

2005